Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
出版年份 2021 全文链接
标题
Efficacy of Cannabidiol for Δ-9-Tetrahydrocannabinol-Induced Psychotic Symptoms, Schizophrenia, and Cannabis Use Disorders: A Narrative Review
作者
关键词
-
出版物
Journal of Clinical Medicine
Volume 10, Issue 6, Pages 1303
出版商
MDPI AG
发表日期
2021-03-22
DOI
10.3390/jcm10061303
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review
- (2020) Jerome Sarris et al. BMC Psychiatry
- Cannabidiol for Mood Disorders: A Call for More Research
- (2020) Francesco Bartoli et al. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
- Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
- (2020) Edward Chesney et al. NEUROPSYCHOPHARMACOLOGY
- Towards Better Delivery of Cannabidiol (CBD)
- (2020) Sophie Anne Millar et al. Pharmaceuticals
- Measuring Disturbance of the Endocannabinoid System in Psychosis
- (2019) Amedeo Minichino et al. JAMA Psychiatry
- The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review
- (2019) Albert Batalla et al. Journal of Clinical Medicine
- Cannabis use disorders among adults in the United States during a time of increasing use of cannabis
- (2019) Wilson M. Compton et al. DRUG AND ALCOHOL DEPENDENCE
- Antipsychotic treatment failure in patients with psychosis and co-morbid cannabis use: A systematic review
- (2019) Sam Reid et al. PSYCHIATRY RESEARCH
- Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial
- (2018) Philip McGuire et al. AMERICAN JOURNAL OF PSYCHIATRY
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
- (2018) Douglas L. Boggs et al. PSYCHOPHARMACOLOGY
- Oxidative Stress and Inflammation in First-Episode Psychosis: A Systematic Review and Meta-analysis
- (2018) David Fraguas et al. SCHIZOPHRENIA BULLETIN
- Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function
- (2018) Celia J. A. Morgan et al. Translational Psychiatry
- Marijuana Legalization: Impact on Physicians and Public Health
- (2016) Samuel T. Wilkinson et al. Annual Review of Medicine
- Therapeutic Potential of Cannabinoids in Psychosis
- (2016) F. Markus Leweke et al. BIOLOGICAL PSYCHIATRY
- ACNP 55th Annual Meeting: Poster Session III
- (2016) NEUROPSYCHOPHARMACOLOGY
- Psychosocial functioning, quality of life and clinical correlates of comorbid alcohol and drug dependence syndromes in people with schizophrenia across Europe
- (2016) Giuseppe Carrà et al. PSYCHIATRY RESEARCH
- Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis
- (2016) Robin M. Murray et al. World Psychiatry
- Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use
- (2015) Hannah Myles et al. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
- Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor
- (2015) R B Laprairie et al. BRITISH JOURNAL OF PHARMACOLOGY
- Correlates of dependence and treatment for substance use among people with comorbid severe mental and substance use disorders
- (2015) Giuseppe Carrà et al. COMPREHENSIVE PSYCHIATRY
- Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol
- (2015) Felipe V. Gomes et al. SCHIZOPHRENIA RESEARCH
- A systematic review of the antipsychotic properties of cannabidiol in humans
- (2015) Tabitha A. Iseger et al. SCHIZOPHRENIA RESEARCH
- Immune system: A possible nexus between cannabinoids and psychosis
- (2014) Paula Suárez-Pinilla et al. BRAIN BEHAVIOR AND IMMUNITY
- Neuroimaging Studies of Acute Effects of THC and CBD in Humans and Animals: a Systematic Review
- (2014) A. Batalla et al. CURRENT PHARMACEUTICAL DESIGN
- Induction of Psychosis byΔ9-Tetrahydrocannabinol Reflects Modulation of Prefrontal and Striatal Function During Attentional Salience Processing
- (2012) Sagnik Bhattacharyya ARCHIVES OF GENERAL PSYCHIATRY
- Treatment of Cannabis Use Among People with Psychotic Disorders: A Critical Review of Randomised Controlled Trials
- (2012) Amanda L. Baker et al. CURRENT PHARMACEUTICAL DESIGN
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment
- (2012) Amir Englund et al. JOURNAL OF PSYCHOPHARMACOLOGY
- Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia
- (2012) F M Leweke et al. Translational Psychiatry
- Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD)
- (2010) Jaime E. C. Hallak et al. REVISTA BRASILEIRA DE PSIQUIATRIA
- Treatment of cannabis use disorders in people with schizophrenia spectrum disorders — A systematic review
- (2009) Carsten Hjorthøj et al. ADDICTIVE BEHAVIORS
- High-potency cannabis and the risk of psychosis
- (2009) Marta Di Forti et al. BRITISH JOURNAL OF PSYCHIATRY
- Opposite Effects of Δ-9-Tetrahydrocannabinol and Cannabidiol on Human Brain Function and Psychopathology
- (2009) Sagnik Bhattacharyya et al. NEUROPSYCHOPHARMACOLOGY
- Rate of Cannabis Use Disorders in Clinical Samples of Patients With Schizophrenia: A Meta-analysis
- (2009) J. Koskinen et al. SCHIZOPHRENIA BULLETIN
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now